Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing with the 24-hour CLSI BMD method for testing susceptibility of Candida species to fluconazole, posaconazole, and voriconazole by use of epidemiological cutoff values

Journal of Clinical Microbiology

Volumn 49, Issue 3, 2011, Pages 845-850

  Pfaller, M A ^a   Espinel Ingroff, A ^b   Boyken, L ^a   Hollis, R J ^a   Kroeger, J ^a   Messer, S A ^a   Tendolkar, S ^a   Diekema, D J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLINICAL AND LABORATORY STANDARDS INSTITUTE; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; EUROPEAN COMMITTEE ON ANTIMICROBIAL SUSCEPTIBILITY TESTING; INTERMETHOD COMPARISON; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; REFERENCE VALUE; STRAIN DIFFERENCE; WILD TYPE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 79952347827     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02441-10     Document Type: Article

References (37)

1. Alexander, B. D., W. A. Schell, J. L. Miller, G. D. Long, and J. R. Perfect. 2005. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 80:868-871.
2. Antoniadou, A., et al. 2003. Candidemia in a tertiary care center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 82:309-321. (Pubitemid 37229466)
3. Chen, A., and J. D. Sobel. 2005. Emerging azole antifungals. Expert Opin. Emerg. Drugs 10:21-33.
4. Chryssanthou, E., and M. Cuenca-Estrella. 2002. Comparison of the Anti-fungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J. Clin. Microbiol. 40:3841-3844.
5. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts: 3rd ed. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Cornely, O. A., et al. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
7. Cuenca-Estrella, M., et al. 2002. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob. Agents Chemother. 46:3644-3647. (Pubitemid 35192943)
8. Diekema, D. J., et al. 2009. A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. Diagn. Microbiol. Infect. Dis. 63:233-236.
9. Espinel-Ingroff, A. 2003. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev. Iberoam. Micol. 20:121-136.
10. Espinel-Ingroff, A., et al. 2005. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J. Clin. Microbiol. 43:3884-3889.
11. European Committee on Antimicrobial Susceptibility Testing, Subcommittee on Antifungal Susceptibility Testing. 2008. EUCAST technical note on fluconazole. Clin. Microbiol. Infect. 14:193-195.
12. European Committee on Antimicrobial Susceptibility Testing, Subcommittee on Antifungal Susceptibility Testing. 2008. EUCAST technical note on voriconazole. Clin. Microbiol. Infect. 14:985-987.
13. Hazen, K. C., and S. A. Howell. 2007. Candida, Cryptococcus, and other yeasts of medical importance, p. 1762-1788. In P. R. Murray, E. J. Brown, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed., vol. 2. ASM Press, Washington, DC.
14. Kahlmeter, G., et al. 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother. 52:145-148.
15. Kahlmeter, G., and D. F. J. Brown. 2004. Harmonization of antimicrobial breakpoints in Europe: can it be achieved? Clin. Microbiol. Newsl. 26:187-192.
16. Kullberg, B. J., et al. 2005. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet 366:1435-1442. (Pubitemid 41483809)
17. Magill, S. S., C. Shields, C. L. Sears, M. Choti, and W. G. Merz. 2006. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol. 44:529-535.
18. Ostrosky-Zeichner, L., et al. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
19. Oxman, D. A., et al. 2010. Candidemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? J. Antimicrob. Chemother. 65:1460-1465.
20. Panackal, A. A., et al. 2006. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J. Clin. Microbiol. 44:1740-1743. (Pubitemid 43726263)
21. Pfaller, M. A., and D. J. Diekema. 2004. 12 years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of Candida bloodstream isolates. Clin. Microbiol. Infect. 10(Suppl. 1):11-23.
22. Pfaller, M. A., et al. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
23. Pfaller, M. A., and D. J. Diekema. 2007. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J. Invasive Fungal Infect. 1:74-92.
24. Pfaller, M. A., et al. 2008. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp: results from a global antifungal surveillance program. J. Clin. Microbiol. 46:551-559.
25. Pfaller, M. A., and D. J. Diekema. 2010. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole and Candida: time for new clinical breakpoints? Curr. Fungal Infect. Rep. 4:168-174.
26. Pfaller, M. A., et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
27. Pfaller, M. A., et al. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat.13:180-195.
28. Pfaller, M. A., et al. 15 December 2010. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-h CLSI broth microdilution methods. J. Clin. Microbiol. doi:10.1128/JCM.02161-10.
29. Rodriguez-Tudela, J. L., et al. 2007. Statistical analysis of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Def. 71.) and CLSI (M27-A2). J. Clin. Microbiol. 45:109-111.
30. Rodriguez-Tudela, J. L., et al. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
31. Sabatelli, F., et al. 2006. In vitro activity of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015.
32. Sheehan, D. J., C. A. Hitchcock, and C. M. Sibley. 1999. Current and emerging azole antifungal agents. Clin. Microbiol. Rev. 12:40-79.
33. Simjee, S., P. Silley, H. O. Werding, and R. Bywater. 2008. Potential confusion regarding the term "resistance" in epidemiological surveys. J. Antimicrob. Chemother. 61:228-229.
34. Skiest, D. J., et al. 2007. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin. Infect. Dis. 44:607-614.
35. Spanakis, E. K., G. Aperis, and E. Mylonakis. 2006. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin. Infect. Dis. 43:1060-1068.
36. Turnidge, J., G. Kahlmeter, and G. Kronvall. 2006. Statistical characterization of bacterial wild-type MIC distributions and determination of epidemiological cutoff values. Clin. Microbiol. Infect. 12:418-425.
37. Turnidge, J., and D. L. Paterson. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408.